Placental tissue component compositions for treatment of skin defects and methods using same

Patent metadata

Field	Value
Publication number	US-2019350983-A1
Application number	US-201916416875-A
Country	US
Kind code	A1
Filing date	May 20, 2019
Priority date	May 18, 2018
Publication date	Nov 21, 2019
Grant date	—

Abstract

The present disclosure provides methods of treating defects such as wrinkles or scars via a subdermal injection of placental tissue components. It also provides placental tissue compositions maintained within the barrel of a syringe, which may be for use in treating such defects.

First claim

1 . A method of treating a defect in a patient by injecting a composition comprising placental tissue components at the site of the defect wherein the placental tissue components are particles, said particles comprising placental disc and at least one of amniotic membrane, chorionic membrane, and umbilical cord.

2 . (canceled)

3 . The method of claim 2 , wherein the particles comprise placental disc and amniotic membrane.

4 . The method of claim 2 , wherein the particles comprise placental disc and chorionic membrane.

5 . The method of claim 2 , wherein the particles comprise placental disc, amniotic membrane, and chorionic membrane.

6 . The method of claim 2 , wherein the particles comprise placental disc and umbilical cord.

7 . The method of claim 2 , wherein the particles comprise placental disc, amniotic membrane, chorionic membrane, and umbilical cord.

8 . The method of claim 2 , wherein the particles are rehydrated.

9 . (canceled)

10 . The method of claim 2 , wherein the particles are micronized.

11 . (canceled)

12 . (canceled)

13 . The method of claim 1 , wherein the defect is selected from the group consisting of scars and wrinkles.

14 . The method of claim 1 , wherein the placental tissue components comprise about 1-20% dehydrated amniotic membrane and/or chorionic membrane particles if present, about 1-30% dehydrated umbilical cord particles if present, and about 50-98% dehydrated placental disc particles, by weight.

15 - 17 . (canceled)

18 . A placental tissue composition maintained within the barrel of a syringe, said placental tissue composition comprising particles of placental disc and at least one of amniotic membrane, chorionic membrane, and umbilical cord.

19 . (canceled)

20 . The composition of claim 19 , wherein the particles comprise placental disc and amniotic membrane.

21 . The composition of claim 19 , wherein the particles comprise placental disc and chorionic membrane.

22 . The composition of claim 19 , wherein the particles comprise placental disc, amniotic membrane, and chorionic membrane.

23 . The composition of claim 19 , wherein the particles comprise placental disc and umbilical cord.

24 . The composition of claim 19 , wherein the particles comprise placental disc, amniotic membrane, chorionic membrane, and umbilical cord.

25 . The composition of claim 19 , wherein the particles are rehydrated.

26 . (canceled)

27 . The composition of claim 19 , wherein said particles are micronized.

28 . (canceled)

29 . (canceled)

30 . The composition of claim 18 , wherein the placental tissue components comprise about 1-20% dehydrated amniotic membrane and/or chorionic membrane particles if present, about 1-30% dehydrated umbilical cord particles if present, and about 50-98% dehydrated placental disc particles, by weight.

31 . (canceled)

32 . The composition of claim 18 , for use in treating a scar or a wrinkle.

Assignees

• Mimedx Group Inc

Inventors

• Levaughn Rick
• Arjunon Sivakkumar
• Taylor Olivia

Classifications

• A61K35/51

  Umbilical cord; Umbilical cord blood; Umbilical stem cells · CPC title

• A61K35/50 Primary

  Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K9/19

  lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)} · CPC title

• A61K9/146

  with organic macromolecular compounds · CPC title